A patient has died following treatment with Elevidys, the Sarepta Therapeutics product that is the only FDA-approved gene therapy for Duchenne muscular dystrophy, the company disclosed Tuesday.

and says the patient is just being dramatic and still ignored us telling him we can't get a pulse," Khayree Burks, wrote on Facebook a few days after Beesler's death. Burks said that Schumann ...

When I meet a patient with a complicated medical history, I often start by asking when they were last perfectly well. Darcie couldn’t remember ever being truly well. Darcie is 20 years old.

Laura Delano walked away from the treatments that defined her teens and 20s. Now, she’s hoping to create a road map for others to follow. Between the ages of 13 and 27, Laura Delano was ...

Meanwhile, the White House’s top health-care policymakers warn that those very price controls will kill American patients, undermine our economy and ultimately increase government health-care ...

Doctors recently implanted an artificial penile prosthesis, a three-piece device, into the body of a patient with erectile dysfunction. A button on the device can be pushed to produce an erection. The ...

For many patients, particularly those in remote regions, telemedicine has the potential to be a lifesaving innovation. However, if key challenges are not addressed, patients—the very people this ...

But he was still in pain, unsteady on his feet — unready for independence. Patients nationwide often stall at this intersection, stuck in the hospital for days or weeks because nursing homes and ...

The Khyber-Pakhtunkhwa government has finalized a plan to provide compensation to the heirs of patients who die during treatment under the Sehat Card program. A formal code of conduct has been ...

Subscribe to our newsletter and stay updated on the latest developments and special offers!

UCSF is recognized globally for innovative treatments, advanced technology and pioneering research applied to patient care. Our team of physicians includes leading experts in virtually all specialties ...

chemotherapy, with a median PFS of 5.59 months vs. 3.98 months. Patients on Elahere have a median overall survival of 16.85 months, a 32% lower risk of death vs. chemotherapy's 13.34 months.